Retraction: The Association of HMGB1 Gene with the Prognosis of HCC (PLoS ONE (2014) 9:2 (e89097) DOI: 10.1371/journal.pone.0089097);The association of HMGB1 gene with the prognosis of HCC

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Xiao, Jianbiao ^a   Ding, Yi ^a   Huang, Jing ^a,c   Li, Qisheng ^a   Liu, Ying ^a   Ni, Wen ^a   Zhang, Yuqin ^a   Zhu, Yanfei ^a   Chen, Longhua ^a   Chen, Bin ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; PLASMID DNA; SMALL INTERFERING RNA; HMGB1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HMGB1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; AGED; CARCINOMA, HEPATOCELLULAR; GENETICS; HEPG2 CELL LINE; LIVER NEOPLASMS; MORTALITY; PROGNOSIS; SURVIVAL; TUMOR CELL CULTURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HEP G2 CELLS; HMGB1 PROTEIN; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84896778685     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0284595     Document Type: Erratum

References (35)

1. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-17. (Pubitemid 37518510)
2. Block TM, Mehta AS, Fimmel CJ, Jordan R (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene 22:5093-107. (Pubitemid 37059591)
3. Tung-Ping Poon R, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10-24.
4. Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, et al (2007) Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 102:1661-70; quiz 0, 71.
5. El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127:S27-34.
6. Thomas MB, Zhu AX (2005) Hepatocellular carcinoma: the need for progress. J ClinOncol 23:2892-9. (Pubitemid 46224106)
7. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al (2002) Randomized controlled trial of transarteriallipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-71. (Pubitemid 34454013)
8. Ng KK, Lo CM, Liu CL, Poon RT, Chan SC, et al (2008) Survival analysis of patients with transplantable recurrent hepatocellular carcinoma: implications for salvage liver transplant. Arch Surg 143:68-74; discussion.
9. Kim do Y, Paik YH, Ahn SH, Youn YJ, Choi JW, et al (2007) PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology (Suppl 1):52-7.
10. Ulloa L (2005) The vagus nerve and the nicotinic anti-inflammatory pathway. Nat Rev Drug Discov 4:673-84.
11. Ulloa L, Tracey KJ (2005) The ''cytokine profile'': a code for sepsis. Trends Mol Med 11:56-63.
12. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331-42. (Pubitemid 40516158)
13. Ulloa L, Batliwalla FM, Andersson U, Gregersen PK, Tracey KJ (2003) High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum 48:876-81. (Pubitemid 36418228)
14. Muller S, Ronfani L, Bianchi ME (2004) Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 255:332-43. (Pubitemid 38315274)
15. Bianchi ME (2004) Significant (re)location: how to use chromatin and/or abundant proteins as messages of life and death. Trends Cell Biol 14:287-93.
16. Luis Ulloa, Davorka Messmer (2006) High-mobility group box 1 (HMGB1) protein: Friend and foe. Cytokine & Growth Factor Reviews 17: 189-201.
17. M.T. Lotze, K.J (2005) Tracey, High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal, Nat Rev Immunol 5: 331-342.
18. Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, et al (2001) Bianchi, New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 20:4337-4340. (Pubitemid 32772027)
19. Dong XD, Ito N, Lotze MT, Demarco RA, Popovic P, et al (2007) High mobility group box 1(HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. Immunother 30: 596-606. (Pubitemid 47229694)
20. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, et al (2007) Masquerader: high mobility group box-1 and cancer, Clin. Cancer Res 13: 2836-2848. (Pubitemid 46850704)
21. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, et al (2003) HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 17:1295-1297.
22. Poser I, Golob M, Buettner R, Bosserhoff AK (2003) Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 23:2991-2998. (Pubitemid 36403094)
23. Akaike H, Kono K, Sugai H, Takahashi A, Mimura K, et al (2007) Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 27:449-457.
24. Volp K, Brezniceanu ML, Bosser S, Brabletz T, Kirchner T, et al (2006) Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 55: 234-242. (Pubitemid 43117284)
25. Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, et al (2003) Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 63:2188-2193. (Pubitemid 36538625)
26. Yongfeng Xu, Yong Yi, Shuangjian Qiu (2010) PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. Journal of Hepatology 53: 872-879.
27. Wu D, Ding YWang S, Zhang Q and Liu L (2008) Increased expression of high mobility group box 1(HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 216: 167-175.
28. Zhang HK, Pan K, Wang H, Weng DS, Song HF, et al (2008) Decreased expression of ING2 gene and its clinicopathological significance in hepatocellular carcinoma. Cancer Lett 261:183-192.
29. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, et al (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196:163-170. (Pubitemid 34110897)
30. Maeda S, Hikiba Y, Shibata W, Ohmae T, Yanai A, et al (2007) Essential roles of high-mobility group box 1 in the development of murine colitis and colitisassociated cancer. BiochemBiophys Res Commun 360:394-400. (Pubitemid 47030357)
31. Rudmik LR, Magliocco AM (2005) Molecular mechanisms of hepatic metastasis in colorectal cancer. J SurgOncol 92:347-359. (Pubitemid 41779295)
32. Kumar S, Weaver VM (2009) Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev 28:113-127.
33. Naghavi MH, Nowak P, Andersson J (2003) Intracellular high mobility group B1 protein(HMGB1) represses HIV-1 LTRdirected transcription in a promoterand cell-specific manner. Virology 314:179-189. (Pubitemid 37153308)
34. Kostova N, Zlateva S, Ugrinova I, Pasheva E (2010) The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem337:251-258.
35. Tang D, Kang R, Zeh HJ, Lotze MT (2010) High-mobility group box 1 and cancer. BiochimBiophysActa 1799:131-140.